AstraZeneca Claims Dual Lung Cancer Phase 3 Wins, but Bispecific Failure Steals the Headline

STRATEGIC NEWS WATCH — August 17, 2026

AstraZeneca’s dual phase 3 lung cancer wins were overshadowed by the failure of its PD-1/CTLA-4 bispecific antibody, on a day when big pharma leaned on partnerships and portfolio pruning — Sandoz-Henlius biosimilars, Lilly-OmniAb ion channels, Novo Nordisk-AWS AI, and J&J’s CAR-T hand-back — to reshape pipelines around externally sourced innovation.

Today’s top developments:

AstraZeneca reported positive phase 3 results for Enhertu and the Orpathys-plus-Tagrisso combination in lung cancer, but a simultaneous failure of its PD-1/CTLA-4 bispecific antibody blunted the momentum and dealt a meaningful setback to its next-generation checkpoint-combination strategy (Fierce Pharma)
Lantheus Holdings won FDA approval for a radiodiagnostic that detects tau neurofibrillary-tangle pathology in cognitively impaired patients, adding a precision imaging tool to Alzheimer’s diagnostic infrastructure as anti-amyloid and anti-tau therapies advance and demand for patient stratification grows (Pharmaceutical Technology)
Sandoz and China-based Henlius struck a $322 million strategic collaboration covering up to 10 biosimilars, explicitly aimed at capturing share as a wave of global biologic loss-of-exclusivities reshapes the market over the next decade (Pharmaceutical Technology)
Eli Lilly signed a global collaboration and license agreement with antibody-platform company OmniAb for a new ion-channel program, paying an undisclosed upfront plus up to $370 million in milestones — with neither target nor modality disclosed — underscoring big-pharma’s appetite for platform-enabled discovery against hard-to-drug targets (Fierce Biotech)
Johnson & Johnson handed global rights to the dual-targeting (CD19/CD20) CAR-T therapy prizlon-cel back to developer AbelZeta — after paying $245 million upfront in 2023 — even as it commits up to $925 million to a Sail Biomedicines in vivo CAR-T pact, signaling a concentration of bets on next-generation cell-therapy platforms (BioSpace)

What to Watch

AstraZeneca bispecific fallout — The failure of AstraZeneca’s PD-1/CTLA-4 bispecific will prompt fresh re-evaluation of similar next-generation checkpoint programs across the industry; expect pipeline-guidance updates and competitor repositioning at upcoming oncology congresses.
Big pharma CAR-T reshuffling — J&J’s return of prizlon-cel to AbelZeta alongside its up-to-$925 million Sail Biomedicines in vivo pact points to a portfolio pivot; the open question is which next-generation cell-therapy platforms attract capital and which assets get pruned.
Sandoz-Henlius biosimilar buildout — With up to 10 biosimilars in scope, execution on the Henlius collaboration becomes a key test of whether Sandoz can strengthen its position ahead of major biologic patent cliffs; asset disclosures and regulatory submissions will be the early signposts.
GLP-1 spillover into consumer health — Nestlé’s push to build nutrition products for weight-loss-drug users underscores how the obesity-drug wave is reshaping adjacent markets; monitor competing food, supplement and device entrants targeting muscle loss and other side effects.
AI-enabled discovery partnerships — Novo Nordisk’s AWS alliance and Lilly’s OmniAb deal both point to platform- and cloud-enabled discovery displacing internal-only research; the signal to track is whether externalization accelerates as large pharma chases pipeline velocity beyond flagship franchises.

This brief highlights the edition’s top stories. Read the full August 17, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.

Related Stories

FDA Oncology Chief Sets Out His Agenda — and Narrows the Etcamah Precedent

Bayer’s Hyrnuo Wins Accelerated Frontline Approval in HER2-Mutant NSCLC, Seven Months Behind Boehringer

FDA Names Permanent CDER and CBER Directors While the Commissioner’s Post Awaits Confirmation